MCID: SVR002
MIFTS: 37

Severe Nonproliferative Diabetic Retinopathy

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Severe Nonproliferative Diabetic Retinopathy

MalaCards integrated aliases for Severe Nonproliferative Diabetic Retinopathy:

Name: Severe Nonproliferative Diabetic Retinopathy 12 15 71
High Risk Non Proliferative Diabetic Retinopathy 12
Severe Npdr 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8946
ICD9CM 34 362.06
SNOMED-CT 67 312905005
UMLS 71 C0730278

Summaries for Severe Nonproliferative Diabetic Retinopathy

MalaCards based summary : Severe Nonproliferative Diabetic Retinopathy, also known as high risk non proliferative diabetic retinopathy, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 5. An important gene associated with Severe Nonproliferative Diabetic Retinopathy is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are p70S6K Signaling and MAPK signaling pathway. The drugs Bevacizumab and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are immune system and renal/urinary system

Related Diseases for Severe Nonproliferative Diabetic Retinopathy

Diseases related to Severe Nonproliferative Diabetic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 30.0 VEGFA PRKCB INS ICAM1 CCL2 AKR1B1
2 microvascular complications of diabetes 5 29.7 VEGFA PRKCB PGF INS ICAM1 ALB
3 diabetic macular edema 29.5 VEGFA REN PRKCB PGF ICAM1 CCL2
4 macular retinal edema 28.9 VEGFA PRKCB PGF INS ICAM1 CCL2
5 background diabetic retinopathy 27.8 VEGFA RRBP1 PGF INS ICAM1 GADD45G
6 retroperitoneal hemangiopericytoma 10.5 VEGFA INS
7 heterophyiasis 10.4 ICAM1 ALB
8 acroosteolysis 10.4 VEGFA ALB
9 critical illness polyneuropathy 10.4 INS ALB
10 microvascular complications of diabetes 2 10.4
11 hypoglycemic coma 10.4 VEGFA INS
12 inflammatory and toxic neuropathy 10.3 INS ALB
13 decubitus ulcer 10.3 VEGFA INS ALB
14 glomerular disease 10.3 ALB ACE
15 chronic ulcer of skin 10.3 VEGFA INS ALB
16 silent myocardial infarction 10.3 INS ACE
17 diabetic cataract 10.3 VEGFA INS AKR1B1
18 diabetic polyneuropathy 10.3 VEGFA INS AKR1B1
19 cancer-associated retinopathy 10.3 VEGFA PGF
20 hypoaldosteronism 10.3 REN ACE
21 renal artery obstruction 10.3 REN ACE
22 mediastinitis 10.3 INS ALB
23 epithelioid hemangioendothelioma 10.3 VEGFA PGF
24 idiopathic nephrotic syndrome 10.3 ALB ACE
25 hypertension, diastolic 10.3 REN ACE
26 hair disease 10.3 VEGFA INS ALB
27 rheumatoid vasculitis 10.3 REN ICAM1
28 idiopathic edema 10.3 INS ACE
29 hepatic vascular disease 10.3 VEGFA REN ALB
30 blood group, globoside system 10.3 VEGFA PGF ALB
31 intussusception 10.3 VEGFA PGF ALB
32 marasmus 10.3 INS ALB
33 cholesterol embolism 10.2 REN ACE
34 macular dystrophy, dominant cystoid 10.2 VEGFA PRKCB ACE
35 parathyroid gland disease 10.2 REN INS ALB
36 hypertensive nephropathy 10.2 VEGFA ALB ACE
37 drug allergy 10.2 INS ALB ACE
38 transient refractive change 10.2 INS AKR1B1
39 corneal disease 10.2 VEGFA ALB AKR1B1
40 maturity-onset diabetes of the young, type 1 10.2 INS ALB ACE
41 placenta disease 10.2 VEGFA PGF INS
42 pulmonary artery disease 10.2 VEGFA ALB ACE
43 severe pre-eclampsia 10.2 VEGFA PGF ALB
44 herpes simplex virus keratitis 10.2 ICAM1 CCL2
45 sexual disorder 10.2 INS ALB ACE
46 malignant renovascular hypertension 10.2 REN PGF
47 exanthem 10.2 VEGFA ALB ACE
48 prediabetes syndrome 10.2 INS ALB ACE
49 thyroid gland disease 10.2 INS ALB ACE
50 potter's syndrome 10.2 REN INS ACE

Graphical network of the top 20 diseases related to Severe Nonproliferative Diabetic Retinopathy:



Diseases related to Severe Nonproliferative Diabetic Retinopathy

Symptoms & Phenotypes for Severe Nonproliferative Diabetic Retinopathy

MGI Mouse Phenotypes related to Severe Nonproliferative Diabetic Retinopathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.7 ACE ALB CCL2 GADD45G ICAM1 INS
2 renal/urinary system MP:0005367 9.17 ACE AKR1B1 ALB GADD45G INS REN

Drugs & Therapeutics for Severe Nonproliferative Diabetic Retinopathy

Drugs for Severe Nonproliferative Diabetic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2 Angiogenesis Inhibitors Phase 4
3 Antineoplastic Agents, Immunological Phase 4
4 Anesthetics Phase 4
5
Ranibizumab Approved Phase 3 347396-82-1 459903
6
Fenofibrate Approved Phase 3 49562-28-9 3339
7
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
8 Hypolipidemic Agents Phase 3
9 Lipid Regulating Agents Phase 3
10 Antimetabolites Phase 3
11 Antineoplastic Agents, Hormonal Phase 3
12 Gastrointestinal Agents Phase 3
13
Triamcinolone Approved, Vet_approved 124-94-7 31307
14 triamcinolone acetonide
15 Triamcinolone diacetate
16 Triamcinolone hexacetonide
17 Angiogenesis Inducing Agents

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
2 Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness Completed NCT01504724 Phase 4 bevacizumab
3 Evaluation of Ranibizumab on the Ease of Procedure and Complication Rate in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy Unknown status NCT00516464 Phase 3 Lucentis (ranibizumab)
4 A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy Completed NCT02718326 Phase 3 Intravitreal aflibercept injection [IAI];Sham
5 Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy Recruiting NCT03869931 Phase 3 Fenofibrate
6 An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR) Terminated NCT00248157 Phase 3 Octreotide acetate in microspheres
7 An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR) Terminated NCT00248131 Phase 3 Octreotide acetate in microspheres
8 A Randomized, Double-masked, Multicenter, Placebo Controlled Study of Keluo Xin Capsule on Efficacy and Safety in Patients With Diabetic Retinopathy Unknown status NCT03258242 Phase 2 Keluo Xin capsule;Placebo oral capsule
9 Panretinal Photocoagulation (PRP) vs PRP Combined With Intravitreous Conbercept (IVC) for Severe Nonproliferative Diabetic Retinopathy (nPDR): A Randomized Clinical Trial Recruiting NCT03863535 Conbercept
10 Analysis of Angiogenic Protein and Anti-angiogenic Levels in Eyes With Diabetic Retinopathy. Recruiting NCT02026843
11 Pascal Pan Retinal Photo-Stimulation in Pre-Proliferative Diabetic Retinopathy: a Safety and Efficacy Study Withdrawn NCT02309502

Search NIH Clinical Center for Severe Nonproliferative Diabetic Retinopathy

Genetic Tests for Severe Nonproliferative Diabetic Retinopathy

Anatomical Context for Severe Nonproliferative Diabetic Retinopathy

MalaCards organs/tissues related to Severe Nonproliferative Diabetic Retinopathy:

40
Eye, Endothelial, Retina, Kidney, Skin, Testes

Publications for Severe Nonproliferative Diabetic Retinopathy

Articles related to Severe Nonproliferative Diabetic Retinopathy:

(show top 50) (show all 275)
# Title Authors PMID Year
1
Screening for diabetic retinopathy in diabetic patients with a mydriasis-free, full-field flicker electroretinogram recording device. 61
31720980 2020
2
Use of Smartphones to Detect Diabetic Retinopathy: Scoping Review and Meta-Analysis of Diagnostic Test Accuracy Studies. 61
32347810 2020
3
Visual Acuity Outcomes after Cataract Extraction with Intraocular Lens Implantation in Eyes with Diabetic Retinopathy. 61
32111544 2020
4
Distribution of peripheral lesions identified by mydriatic ultra-wide field fundus imaging in diabetic retinopathy. 61
31989286 2020
5
The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025. 61
31285276 2020
6
Quantification of Retinal Nonperfusion and Neovascularization With Ultrawidefield Fluorescein Angiography in Patients With Diabetes and Associated Characteristics of Advanced Disease. 61
32352506 2020
7
OCT Angiography Assessment of Retinal Microvascular Changes in Diabetic Eyes in an Urban Safety-Net Hospital. 61
31926950 2020
8
Retinal vasculature-function correlation in non-proliferative diabetic retinopathy. 61
31552568 2020
9
Widefield optical coherence tomography angiography for early detection and objective evaluation of proliferative diabetic retinopathy. 61
32193221 2020
10
A Proposed Classification of Intraretinal Microvascular Abnormalities in Diabetic Retinopathy Following Panretinal Photocoagulation. 61
32191287 2020
11
Alteration of choroidal vascular structure in diabetic retinopathy. 61
31177190 2020
12
Medios- An offline, smartphone-based artificial intelligence algorithm for the diagnosis of diabetic retinopathy. 61
31957735 2020
13
The effect of glycaemia on choroidal thickness in different stages of diabetic retinopathy. 61
32036371 2020
14
Disparity of microaneurysm count between ultrawide field colour imaging and ultrawide field fluorescein angiography in eyes with diabetic retinopathy. 61
32111607 2020
15
Optical coherence tomography angiography findings of type 1 diabetic patients with diabetic retinopathy, in comparison with type 2 patients. 61
31832768 2020
16
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. 61
32077907 2020
17
Aflibercept Reduces Retinal Hemorrhages and Intravitreal Microvascular Abnormalities But Not Venous Beading: Secondary Analysis of the CLARITY Study. 61
32473901 2020
18
Validation of Deep Convolutional Neural Network-based algorithm for detection of diabetic retinopathy - Artificial intelligence versus clinician for screening. 61
31957737 2020
19
A convolutional neural network for the screening and staging of diabetic retinopathy. 61
32569310 2020
20
Discordant vascular parameter measurements in diabetic and non-diabetic eyes detected by different optical coherence tomography angiography devices. 61
32544179 2020
21
Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema. 61
32440092 2020
22
Topographic analysis of macular choriocapillaris flow deficits in diabetic retinopathy using swept-source optical coherence tomography angiography. 61
32206342 2020
23
Thinner Average Choroidal Thickness Is a Risk Factor for the Onset of Diabetic Retinopathy. 61
32023612 2020
24
Total Protein Concentration and Tumor Necrosis Factor α in Tears of Nonproliferative Diabetic Retinopathy. 61
31834153 2019
25
Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor. 61
31383483 2019
26
Changing trends in the prevalence of diabetic retinopathy in type 1 diabetes mellitus from 1990 to 2018: A retrospective study in a Portuguese population. 61
31669626 2019
27
Epidemiology of Diabetic Retinopathy at Eye Clinic Svjetlost Sarajevo: Two Years Retrospective Single Center Study. 61
32082096 2019
28
MicroRNAs as biomarkers of diabetic retinopathy and disease progression. 61
31290435 2019
29
Automatic Detection of Diabetic Retinopathy in Retinal Fundus Photographs Based on Deep Learning Algorithm. 61
31737428 2019
30
Quantitative Ultra-Widefield Angiography and Diabetic Retinopathy Severity: An Assessment of Panretinal Leakage Index, Ischemic Index and Microaneurysm Count. 61
31383482 2019
31
Retinal Nonperfusion Relationship to Arteries or Veins Observed on Widefield Optical Coherence Tomography Angiography in Diabetic Retinopathy. 61
31622467 2019
32
An Evaluation System of Fundus Photograph-Based Intelligent Diagnostic Technology for Diabetic Retinopathy and Applicability for Research. 61
31290125 2019
33
Electrophysiological and pupillometric measures of inner retina function in nonproliferative diabetic retinopathy. 61
31016437 2019
34
MicroRNA-Related Genetic Variants Are Associated With Diabetic Retinopathy in Type 1 Diabetes Mellitus. 61
31546259 2019
35
Beyond vision loss: the independent impact of diabetic retinopathy on vision-related quality of life in a Chinese Singaporean population. 61
30361276 2019
36
Use of Telehealth Screening to Detect Diabetic Retinopathy and Other Ocular Findings in Primary Care Settings. 61
30481134 2019
37
Effects of panretinal photocoagulation on retinal vasculature and foveal avascular zone in diabetic retinopathy using optical coherence tomography angiography: A pilot study. 61
31528763 2019
38
EVALUATION OF MULTISPECTRAL IMAGING IN DIAGNOSING DIABETIC RETINOPATHY. 61
29901495 2019
39
The diagnostic accuracy of an intelligent and automated fundus disease image assessment system with lesion quantitative function (SmartEye) in diabetic patients. 61
31412800 2019
40
Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions. 61
30878488 2019
41
Macular vessels density in diabetic retinopathy: quantitative assessment using optical coherence tomography angiography. 61
30194547 2019
42
Central retinal thickness following panretinal photocoagulation using a multispot semi-automated pattern-scanning laser to treat ischaemic diabetic retinopathy: Treatment in one session compared with four monthly sessions. 61
30561087 2019
43
Optical coherence tomography angiography analysis of the choriocapillary layer in treatment-naïve diabetic eyes. 61
31089870 2019
44
Evaluation of blood flow on optic nerve head after pattern scan and conventional laser panretinal photocoagulation. 61
31192968 2019
45
Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. 61
30973596 2019
46
Quantitative analysis of retinal and choroid capillary ischaemia using optical coherence tomography angiography in type 2 diabetes. 61
30810284 2019
47
Impact of Diabetic Retinopathy on Sleep, Mood, and Quality of Life. 61
31117122 2019
48
Validation of Smartphone-Based Retinal Photography for Diabetic Retinopathy Screening. 61
31100178 2019
49
Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial. 61
30676635 2019
50
[Frequency and severity of diabetic retinopathy in patients with type 2 diabetes mellitus at the Regional Institute of Ophthalmology]. 61
31460638 2019

Variations for Severe Nonproliferative Diabetic Retinopathy

Expression for Severe Nonproliferative Diabetic Retinopathy

Search GEO for disease gene expression data for Severe Nonproliferative Diabetic Retinopathy.

Pathways for Severe Nonproliferative Diabetic Retinopathy

Pathways related to Severe Nonproliferative Diabetic Retinopathy according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 REN PRKCB PGF INS CCL2 ACE
2 12.22 VEGFA PRKCB PGF INS GADD45G
3
Show member pathways
12.01 VEGFA PRKCB ICAM1 CCL2
4
Show member pathways
11.89 INS ICAM1 CCL2 ALB
5 11.69 VEGFA ICAM1 CCL2
6 11.65 VEGFA PRKCB INS
7 11.6 PRKCB ICAM1 GADD45G
8 11.51 VEGFA ICAM1 CCL2
9 10.92 VEGFA PRKCB ICAM1 CCL2
10 10.79 VEGFA CCL2
11
Show member pathways
10.7 VEGFA PGF
12 10.68 ICAM1 CCL2

GO Terms for Severe Nonproliferative Diabetic Retinopathy

Cellular components related to Severe Nonproliferative Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 VEGFA REN PGF INS ICAM1 CCL2

Biological processes related to Severe Nonproliferative Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.58 VEGFA REN ACE
2 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.43 VEGFA PRKCB
3 vascular endothelial growth factor signaling pathway GO:0038084 9.37 VEGFA PGF
4 induction of positive chemotaxis GO:0050930 9.32 VEGFA PGF
5 amyloid-beta metabolic process GO:0050435 9.26 REN ACE
6 angiotensin maturation GO:0002003 9.16 REN ACE
7 positive regulation of mast cell chemotaxis GO:0060754 8.96 VEGFA PGF
8 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 8.62 VEGFA ACE

Molecular functions related to Severe Nonproliferative Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor receptor binding GO:0005159 8.96 REN INS
2 vascular endothelial growth factor receptor binding GO:0005172 8.62 VEGFA PGF

Sources for Severe Nonproliferative Diabetic Retinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....